Product Name: SLU-PP-332 Pen 

Formulation: 2.6 mL pre-filled pen 

Clicks per Pen: 240 

Total Amount: 1.3 mg SLU-PP-332 

Supplied with: 6 sterile needles (extras available) 

Description 

SLU-PP-332 is a first-in-class synthetic small-molecule pan-agonist of estrogen-related receptors (ERRA, ERRẞ, and ERRY). It is a non-steroidal, non-endocrine-disrupting compound belonging to the class of ERR agonists. Chemical name: 4-hydroxy-N-(4-(2-(4-hydroxyphenyl)propan-2-yl)phenyl)benzamide (or structural analog thereof; exact proprietary structure is patented by Saint Louis University). SLU-PP-332 is orally bioavailable, metabolically stable, and designed to selectively activate ERRS without binding classical estrogen receptors (ERa/ERẞ). 

Mechanism of Action 

SLU-PP-332 binds directly to the ligand-binding domain of ERRA, ERRẞ, and ERRY, inducing conformational changes that promote coactivator recruitment (e.g., PGC-1a) and transcriptional activation of ERR target genes. Key downstream effects include: 

• Upregulation of mitochondrial biogenesis and oxidative phosphorylation genes 
• Increased expression of fatty acid oxidation enzymes and mitochondrial uncoupling proteins 
• Enhanced type I (slow-twitch, oxidative) muscle fibre gene programs 
• Improved exercise endurance capacity and metabolic flexibility 
• Activation of energy expenditure pathways independent of classical estrogen signalling 
• The compound induces an “exercise-like” molecular signature in skeletal muscle, liver, adipose tissue, and brain, mimicking many of the metabolic adaptations seen with chronic physical training. 

Indications & Usage 

SLU-PP-332 is used to support mitochondrial function, metabolic health, and exercise-like adaptations. It is indicated for: 

• Enhancement of mitochondrial biogenesis and cellular energy production 
• Promotion of fat oxidation, metabolic efficiency, and insulin sensitivity 
• Support for endurance capacity, muscle oxidative phenotype, and recovery from metabolic stress 
• Assistance in age-related or inactivity-related decline in mitochondrial and metabolic performance 

Contraindications & Warnings 

Do not use if you have: 

• Known hypersensitivity to SLU-PP-332 or any excipient 
• Active malignancy (theoretical concern regarding enhanced cellular metabolism) 
• Severe uncontrolled hepatic or renal impairment 
• Pregnancy or breastfeeding 
• Age under 18 years 

Warnings 

• Use only under medical supervision with periodic monitoring (glucose metabolism, liver function, lipid profile, and clinical parameters). 
• Not a substitute for physical exercise, diet, or approved therapies for metabolic disorders. 
• High doses may cause transient gastrointestinal discomfort, flushing, or changes in energy levels. 
• Discontinue immediately and seek medical attention if severe symptoms occur (e.g., severe abdominal pain, allergic reaction, or unexpected neurological changes). 

Dosage & Administration 

• Subcutaneous injection only. 
• Standard Dose: 1.3 mg per injection (full pen content per dose; typically, 240 clicks = 1.3 mg) 
• Frequency: Once daily or 3-5 times per week (depending on protocol and tolerance) 
• Timing: Morning or pre–activity to maximize energy and metabolic effects 
• Cycle: Typically, 4-12 weeks on, followed by 4 weeks off to maintain efficacy 

Administration Instructions

1. Wash hands and prepare a clean surface. 
2. Attach a sterile needle. 
3. Dial the required number of clicks (full dose = 240 clicks for 1.3 mg). 
4. Clean injection site (abdomen or thigh) with alcohol swab. 
5. Insert needle at 45-90° angle and inject slowly. 
6. Withdraw needle, dispose safely, and cap the pen. 
7. Rotate injection sites to minimize irritation. 
8. Always inspect solution before use: Do not inject if cloudy, discoloured, or containing particles. 

Side Effects 

SLU-PP-332 is generally well tolerated in preclinical models. Human data are limited; potential adverse reactions may include: 

• Mild injection-site irritation, redness, or itching 
• Transient headache, light-headedness, or flushing 
• Temporary gastrointestinal discomfort (nausea, bloating) 
• Rare fatigue or changes in energy levels during initial use 
• If any severe or persistent symptoms occur (e.g., severe headache, abdominal pain, or allergic signs), discontinue use and contact your healthcare provider immediately. 

Storage & Handling 

• Store either in refrigerator (fridge); never freeze or in a cool dry place (≤25-30°C/77-86°F). 
• Keep pen capped and protected from light and heat. 
• After first use: Same storage conditions. 
• Keep out of reach of children. 
• Discard if expired or solution appears abnormal. 

Powered by Precision MSSPT 

Peptide Pen formulations set the standard for research peptide delivery in challenging environments. Powered by exclusive MSSPT, each pen combines buffers, antioxidants, and proprietary agents in a compact, user-friendly injector, delivering strict control over pH, light, oxygen, oxidative factors, and moisture even under South Africa’s subtropical variability or the UAE’s extreme desert heat and humidity. This proprietary technology positions Peptide Pen as the premier choice for researchers in these regions: no mixing, no guesswork, and reliable, high-fidelity results despite demanding protocols and climates. Every Peptide Pen is built for exceptional durability, reliability, and performance- providing precision molecular stabilization in every dose, wherever your research takes you. 

IMPORTANT NOTICE 

This product is not intended to diagnose, treat, cure, or prevent any disease. Statements have not been evaluated by the FDA, SAHPRA, or other authorities. Always consult a licensed healthcare provider before use, especially if pregnant, breastfeeding, under 18, or managing medical conditions.